Effectiveness of oral semaglutide versus empagliflozin for the management of type 2 diabetes. <scp>PIONEER</scp> ‐2 trial emulation with real‐world data
Under routine care, new users of oral semaglutide achieved better glycaemic control compared with empagliflozin new users, with similar weight loss but lower treatment persistence. These findings support the results of PIONEER-2 and its transferability to clinical practice.
Authors
- Agostino Consoli (ORCID: https://orcid.org/0000-0002-1885-451X)
- Enrico Longato (ORCID: https://orcid.org/0000-0001-5940-645X)
- Gian Paolo Fadini (ORCID: https://orcid.org/0000-0002-6510-2097)
- Angelo Avogaro (ORCID: https://orcid.org/0000-0002-1177-0516)
- Maddalena Trombetta (ORCID: https://orcid.org/0000-0002-0825-1117)
- Anna Solini (ORCID: https://orcid.org/0000-0002-7855-8253)
- Giuseppe Penno (ORCID: https://orcid.org/0000-0002-2834-4847)
- Andrea Giaccari (ORCID: https://orcid.org/0000-0002-7462-7792)
- Marco Strazzabosco
- Mariangela Ghiani
- Sara Poletto
Institutions
- Università Cattolica del Sacro Cuore (IT)
- University of Pisa (IT)
- University of Verona (IT)
- University of Padua (IT)
- University of Chieti-Pescara (IT)
- Veneto Institute of Molecular Medicine (IT)
- ASL Roma (IT)
- Azienda Ospedaliero-Universitaria Cagliari (IT)
- Azienda USL di Pescara (IT)
- Ospedale San Bortolo (IT)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-09-24
- DOI
- https://doi.org/10.1111/dom.70151
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00